United Therapeutics (NASDAQ:UTHR) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of United Therapeutics (NASDAQ:UTHR - Free Report) in a research report released on Monday,Benzinga reports. They currently have a $425.00 target price on the biotechnology company's stock. HC Wainwright also issued estimates for United Therapeutics' Q2 2025 earnings at $7.02 EPS, Q3 2025 earnings at $7.03 EPS, Q4 2025 earnings at $6.63 EPS, FY2025 earnings at $27.31 EPS, FY2026 earnings at $29.50 EPS, FY2027 earnings at $32.32 EPS, FY2028 earnings at $34.56 EPS and FY2029 earnings at $36.57 EPS.

Several other research firms have also issued reports on UTHR. UBS Group lifted their target price on United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a research note on Wednesday, January 8th. JPMorgan Chase & Co. lowered their target price on shares of United Therapeutics from $355.00 to $350.00 and set an "overweight" rating for the company in a research note on Thursday, May 1st. Wells Fargo & Company reaffirmed an "equal weight" rating and set a $314.00 price target (down from $395.00) on shares of United Therapeutics in a research report on Friday, April 25th. Morgan Stanley upped their target price on United Therapeutics from $346.00 to $348.00 and gave the company an "equal weight" rating in a research report on Thursday, May 1st. Finally, StockNews.com downgraded shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, May 2nd. Four investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat.com, United Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $392.00.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR traded up $11.94 during trading hours on Monday, hitting $306.96. The company's stock had a trading volume of 525,591 shares, compared to its average volume of 441,022. The firm's fifty day moving average price is $300.72 and its 200 day moving average price is $343.05. United Therapeutics has a 52 week low of $260.41 and a 52 week high of $417.82. The company has a market capitalization of $13.85 billion, a price-to-earnings ratio of 13.48, a P/E/G ratio of 0.97 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, topping analysts' consensus estimates of $6.29 by $0.34. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $794.40 million during the quarter, compared to the consensus estimate of $726.82 million. During the same quarter in the previous year, the firm posted $6.17 earnings per share. United Therapeutics's revenue for the quarter was up 17.2% compared to the same quarter last year. On average, equities research analysts predict that United Therapeutics will post 24.48 earnings per share for the current fiscal year.

Insider Buying and Selling

In other United Therapeutics news, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $300.93, for a total value of $3,310,230.00. Following the completion of the transaction, the executive vice president now owns 36,781 shares of the company's stock, valued at approximately $11,068,506.33. The trade was a 23.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Raymond Dwek sold 4,000 shares of the firm's stock in a transaction dated Monday, April 7th. The shares were sold at an average price of $284.55, for a total value of $1,138,200.00. Following the sale, the director now owns 1,750 shares in the company, valued at $497,962.50. This trade represents a 69.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 75,500 shares of company stock valued at $24,245,880 over the last ninety days. Company insiders own 11.90% of the company's stock.

Hedge Funds Weigh In On United Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in UTHR. Newbridge Financial Services Group Inc. purchased a new position in shares of United Therapeutics in the fourth quarter valued at approximately $25,000. Dunhill Financial LLC boosted its stake in United Therapeutics by 100.0% during the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock worth $35,000 after purchasing an additional 50 shares during the last quarter. Sound Income Strategies LLC acquired a new stake in shares of United Therapeutics in the first quarter valued at about $49,000. State of Wyoming purchased a new position in shares of United Therapeutics in the fourth quarter worth about $62,000. Finally, Millstone Evans Group LLC acquired a new position in United Therapeutics during the fourth quarter worth about $67,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.